Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/04/20 | $20,000,000 | Seed |
Boehringer Ingelheim Venture Fund Kaitai Capital Legend Star Matrix Partners | undisclosed |
| 11/29/22 | $52,000,000 | Series A |
AZ-CICC Healthcare Investment Fund Delos Capital Korean Investment Partners | undisclosed |
